Search for 'Provider:Clinical and au:Pulido Ortega, Federico'

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.

By Pulido Ortega, Federico. HIV clinical trials, 2015 . 16(1):43-8. , Formato Vancouver: Pedrol E, Caro Murillo AM, Castaño MA, Riera M, Olalla J, Domingo P et al. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study. HIV Clin Trials. 2015 Jan-Feb;16(1):43-8.

Place Hold on Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.

Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

By Pulido Ortega, Federico | Rubio García, Rafael . Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2015 . 60(6):950-8. , Formato Vancouver: Berenguer J, Zamora FX, Aldámiz Echevarría T, Von Wichmann MA, Crespo M, López Aldeguer J et al; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2015 Mar 15;60(6):950-8.

Place Hold on Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.

By Delgado Vázquez, Rafael | Pulido Ortega, Federico. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014 . 59(4):578-88. , Formato Vancouver: Pou C, Noguera-Julian M, Pérez-Álvarez S, García F, Delgado R, Dalmau D et al. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. Clin Infect Dis. 2014 Aug 15;59(4):578-88.

Place Hold on Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.

Chagas disease screening among HIV-positive Latin American immigrants: an emerging problem.

By Fiorante, Silvana | Llenas García, Jara | Maseda Fernández, Diego | Matarranz del Amo, Mariano | Pulido Ortega, Federico | Rubio García, Rafael . European Journal of Clinical Microbiology & Infectious Diseases, 2012 . 31(8):1991-7. , Formato Vancouver: Llenas-García J, Hernando A, Fiorante S, Maseda D, Matarranz M, Salto E, et al. Chagas disease screening among HIV-positive Latin American immigrants: an emerging problem. Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1991-7.

Place Hold on Chagas disease screening among HIV-positive Latin American immigrants: an emerging problem.

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the PROGRESS study, 48-week results

By Pulido Ortega, Federico. HIV Clinical Trials, 2011 . 12(5):255-267. , Formato Vancouver: Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. HIV Clin Trials. 2011;12(5):255-67.

Place Hold on Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the PROGRESS study, 48-week results